Why the study?
Does pre-transplant use of amiodarone impact mortality and complications after heart transplantation in patients with severe heart failure?
Does pre-transplant use of amiodarone impact mortality and complications after heart transplantation in patients with severe heart failure?
This review evaluates the controversial impact of pre-transplant amiodarone use on post-transplant mortality and morbidity in severe heart failure patients.
Answers are grounded in this paper and cite their sources.
Pre-transplant amiodarone warrants caution in transplant candidates; leaves open need for prospective data on post-transplant outcomes.
Heart transplantation is the «gold standard» of severe heart failure treatment. Sudden arrhythmic death is the leading cause of death among these patients. Amiodarone is the only antiarrhythmic drug with beneficial effect on survival of patients with end-stage heart failure. Given its long half-life, pre-transplant use of amiodarone has been extensively discussed focusing on divergent results regarding morbidity and mortality after heart transplantation. Its adverse clinical events after transplantation remain debatable. This review is aimed at evaluation of the impact of amiodarone pretransplant use on mortality and complications after heart transplantation.
No takes yet. Share an insight, caveat, or question.
Колоскова et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: